High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala

被引:4
|
作者
Brum-Soares, Lucia [1 ]
Cubides, Juan-Carlos [1 ]
Burgos, Iris [1 ]
Monroy, Carlota [2 ]
Castillo, Leticia [3 ]
Gonzalez, Selene [3 ]
Vinas, Pedro Albajar [4 ]
Palma Urrutia, Pedro Pablo [5 ]
机构
[1] Med Sem Fronteiras, Unidade Med Brasileira, Rio De Janeiro, RJ, Brazil
[2] San Carlos Univ, Lab Med & Parasit Entomol, Guatemala City, Guatemala
[3] Natl Lab Publ Hlth, Dept Parasitol, Guatemala City, Guatemala
[4] WHO, Dept Control Neglected Trop Dis, Geneva, Switzerland
[5] Doctors Borders, Dept Med, Barcelona, Spain
关键词
Benznidazole; Chagas; Chronic infection; Guatemala; Seroconversion; CHRONIC CHAGAS-DISEASE; TRIAL; HONDURAS; SAFETY;
D O I
10.1590/0037-8682-0415-2016
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Introduction: Geographical, epidemiological, and environmental differences associated with therapeutic response to Chagas etiological treatment have been previously discussed. This study describes high seroconversion rates 72 months after benznidazole treatment in patients under 16 years from a project implemented by Doctors without Borders in Guatemala. Methods: An enzyme-linked immunosorbent assay was used to detect Trypanosoma cruzi IgG antibodies in capillary blood samples from patients 72 months after treatment. Fisher's exact test was used to establish association between characteristics, such as sex, age, and origin of patients, and final seroconversion. Kappa index determined concordance between laboratory tests. The level of significance was set to 5%. Results: Ninety-eight patients, aged 6 months to 16 years, were available for follow-up. Sex and origin were not associated with seroconversion. Individuals older than 13 were more prone to maintain a positive result 72 months after treatment, although results were not highly significant. Laboratory tests presented elevated Kappa concordance (95% CI) = 0.8290 (0.4955-1), as well as high (97%) seroconversion rates. Conclusions: The high seroconversion rate found in this study emphasizes the importance of access to diagnosis, treatment, and follow-up of individuals affected by Chagas disease. Moreover, it contradicts the idea that it is not possible to achieve a cure with the currently available drugs. This study strongly supports expanding programs for patients infected with T. cruzi in endemic and non-endemic countries.
引用
收藏
页码:721 / 727
页数:7
相关论文
共 37 条
  • [31] High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study
    Gupta, Neil
    Kabahizi, Jules
    Muvunyi, Claude
    Mbituyumuremyi, Aimble
    Van Nuil, Jennifer I.
    Grant, Philip M.
    HEPATOLOGY, 2017, 66 : 615A - 615A
  • [32] In Vitro Infection of Trypanosoma cruzi Causes Decrease in Glucose Transporter Protein-1 (GLUT1) Expression in Explants of Human Placental Villi Cultured under Normal and High Glucose Concentrations
    Mezzano, Luciana
    Repossi, Gaston
    Fretes, Ricardo E.
    Lin, Susana
    Sartori, Maria Jose
    de Fabro, Sofia G. Parisi
    JOURNAL OF TROPICAL MEDICINE, 2012, 2012
  • [33] HIGH RATES OF HEPATITIS B VIRUS (HBV) FLARE AND REACTIVATION AMONG PATIENTS WITH CHRONIC INACTIVE HBV AND PRIOR RESOLVED HBV INFECTION TREATED WITH RITUXIMAB
    Junus, K.
    Aguilar, M.
    Patel, P.
    Irwin, D.
    Yee, S.
    Liu, B.
    Bhuket, T.
    Wong, R.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S376 - S376
  • [34] Hidden high-grade vesicoureteral reflux is the main risk factor for chronic renal damage in children under the age of two years with first urinary tract infection
    Zaffanello, Marco
    Cataldi, Luigi
    Brugnara, Milena
    Franchini, Massimo
    Bruno, Costanza
    Fanos, Vassilios
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2009, 43 (06): : 494 - 500
  • [36] High Sustained Virologic Response (SVR) Rates in Patients with Chronic HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/MK-8408 Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of C-CREST-1 & 2)
    Serfaty, Lawrence
    Pianko, Stephen
    Ben Ari, Ziv
    Laursen, Alex L.
    Hansen, Jesper
    Gane, Edward J.
    Huang, Hsueh-cheng
    Jin, Shu
    Bourque, Jennifer
    Fernsler, Doreen
    Wan, Shuyan
    Dutko, Frank
    Nguyen, Bach-Yen T.
    Wahl, Janice
    Barr, Eliav
    Butterton, Joan R.
    HEPATOLOGY, 2016, 64 : 61A - 62A
  • [37] High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)
    Serfaty, L.
    Pianko, S.
    Ari, Z. B.
    Laursen, A. L.
    Hansen, J.
    Gane, E. J.
    Huang, H. -C.
    Jin, S.
    Bourque, J.
    Liu, H.
    Grandhi, A.
    Su, M.
    Gendrano, N.
    Fernsler, D.
    Dutko, F.
    Nguyen, B. -Y. T.
    Wahl, J.
    Barr, E.
    Yeh, W.
    Plank, R.
    Butterton, J. R.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S306 - S307